Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
04.12.24 | AstraZeneca's Enhertu and Akeso's bispecifics win national coverage in China as CAR-T therapies miss out again | ||
04.12.24 | Klick Health uses AI to orchestrate 'Holiday Hugs' after survey shows scarcity in year-round embraces | ||
04.12.24 | With AstraZeneca exec under investigation in China, company names Reic new international chief | ||
04.12.24 | Sumitomo brings together Gemtesa 'Go-Getters' to discuss overactive bladder symptoms | ||
04.12.24 | Novavax scores $200M as it hands over keys to Czech production plant-along with 300 employees-to Novo Nordisk | ||
04.12.24 | Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial | ||
03.12.24 | Coherus sells its last biosimilar Udenyca to Intas for up to $558M as company homes in on novel cancer meds | ||
03.12.24 | IRA price negotiations and M&A among topics to watch after 'Republican Red Wave,' analyst group says | ||
03.12.24 | CSL Seqirus inks bird flu vaccine supply pact with UK after similar deals in US, Europe | ||
03.12.24 | Reckitt shells out $200M to expand its Mucinex production site in North Carolina | ||
03.12.24 | Lil Jon delivers scat rap, duets with singing toilet to promote Exact Sciences' cancer kit | ||
03.12.24 | Agenus to offer CDMO services as part of its latest reorganization | ||
03.12.24 | RFK Jr. could 'cost lives in this country' if he pursues changes to US vaccine policy, Gottlieb says | ||
02.12.24 | After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe | ||
02.12.24 | Quantoom, Univercells and Fiocruz ink collaboration to bolster RNA-based vaccines in Brazil and beyond | ||
02.12.24 | FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports | ||
02.12.24 | Sanofi charts biggest China investment to date with plans for €1B insulin 'manufacturing base' in Beijing | ||
02.12.24 | GSK takes AMR message to Paddington, bearing responsibility for raising awareness of risks | ||
02.12.24 | Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market | ||
27.11.24 | FDA oncology advisory committee to weigh Exelixis' Cabometyx in neuroendocrine tumors | ||
27.11.24 | Sanofi opens $590M modular vaccine, biologics plant in Singapore | ||
27.11.24 | Kelun's Merck-partnered ADC snags first nod in China to kick off TROP2 fight with Gilead | ||
27.11.24 | With narcolepsy trial win, Axsome looks to revive former Pfizer antidepressant on the US market | ||
27.11.24 | Most life sciences CEOs expect to grow their head counts over the next 3 years: KPMG survey | ||
26.11.24 | Novartis plots more than 100 layoffs in New Jersey as part of rework to Xolair, cancer combo field sales teams |